Delivering Value in Healthcare: A Multi-Stakeholder Vision for Innovation

Myriad Middle Ground

2Q13 Financial Markets Preview

Big Brain Science

Jump-starting triple-negative

The Ugly Underbelly

3Q Financial Markets Preview: Avoiding burnout

2Q 2012 Biotech Stocks: Some Like It Hot

A Longer Weight

Provenge Politics

Back to School Issue: Innovation & Collaboration

3Q Financial Markets Preview: Flavored with Phase III

Progressive thinking for FDA

MODDERN Thinking

A CATT in the hat tale

Biosimilars two-step

KV at the brink

Curing cancer trials

Sweet Spot revisited

Lost in translation

Obesity Reset

The Low Road

Cover Story: Buyside View XIX: Commercial Risk

Innovators pick China

New Diagnostics Pathway

Regulation: Mild Was Enough

Wanted: Less Dilution

Regulation: The Provenge Messages

4Q Financial Markets Preview: Watershed Moment including
the 4Q10 Milestones

Regulation: Obesity Obstacles

Thalidomide 50 Years Later

Back to School Issue: Regulatory innovation

Politics, Policy & Law: Commentary: AHA Moment for Free Speech

8th Annual Iceberg Review of Euro Biotech

Europe's Iceberg 2010: Performance Counts

Politics, Policy & Law: Commentary: Let There Be Hype

Visit BioCentury.com for more information.